» Articles » PMID: 32252669

Ammonia and Coma - a Case Report of Late Onset Hemizygous Ornithine Carbamyltransferase Deficiency in 68-year-old Female

Overview
Journal BMC Neurol
Publisher Biomed Central
Specialty Neurology
Date 2020 Apr 8
PMID 32252669
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Acute hyperammonemia without signs of common causes in the elderly might be challenging to identify. We report the oldest case known to date of a female patient with late onset ornithine carbamyltransferase deficiency (OTC), which was unmasked after a protein overload due to nutritional supplements. Our case illustrates how environmental factors (protein overload) in previously unknown OTC in the elderly leads to hyperammonemic encephalopathy and highlights that early treatment prevents persisting neurological deficits and should be considered in absence of common causes of hyperammonemic encephalopathy.

Case Presentation: A 68-year-old woman presented with acute confusion, which progressed into a deep coma (Glasgow-Coma-Scale score 3) within a few hours. The only remarkable finding was a plasma ammonia (NH3) concentration of 697 μmmol/l (range 12-47 μmmol/). Third party history revealed that the patient disliked meat for most of her life (meat = protein, which needs to be metabolized) and had taken nutritional supplements (since supplements often have a high protein-ratio) 2 days before the symptoms started. Protein catabolism results in NH3, which is metabolized via the urea cycle. Consequently, the acute hyperammonemia in our patient was thought to be related to an inherited metabolic disorder, which only unmasked itself as a result of an overload of the corresponding metabolite (in this case protein). Since ornithine carbamyltransferase deficiency (OTC) is the most common inherited urea cycle disorder, this diagnosis became likely and was confirmed later via genetic and metabolic testing (amino acids, orotic acid, etc.). After 2 weeks of treatment (dialysis, low-protein-diet, nitrogen-lowering medication) the patient was discharged in a healthy condition without any neurological deficits.

Conclusion: OTC is a x-chromosomal linked disorder, that usually manifests in newborn infants and children, but also rarely in adults and even rarer in the elderly (50- till 60-years-old), where it is probably underdiagnosed. In case of hyperammonemic encephalopathy - regardless of the underlying cause -, treatment should be started early to prevent persisting neurological deficits. OTC should be considered in absence of common causes of hyperammonemic encephalopathy.

Citing Articles

Histopathological examination of characteristic brain MRI findings in acute hyperammonemic encephalopathy: A case report and review of the literature.

Denk C, Kunzmann J, Maieron A, Wohrer A, Quinot V, Oberndorfer S Neuroradiol J. 2023; 37(5):630-635.

PMID: 37915221 PMC: 11444322. DOI: 10.1177/19714009231212370.


Diagnostic and Management Issues in Patients with Late-Onset Ornithine Transcarbamylase Deficiency.

Ibrahim M, Gold J, Woodall A, Yilmaz B, Gissen P, Stepien K Children (Basel). 2023; 10(8).

PMID: 37628367 PMC: 10453542. DOI: 10.3390/children10081368.

References
1.
Klein O, Kostiner D, Weisiger K, Moffatt E, Lindeman N, Goodman S . Acute fatal presentation of ornithine transcarbamylase deficiency in a previously healthy male. Hepatol Int. 2009; 2(3):390-4. PMC: 2716892. DOI: 10.1007/s12072-008-9078-x. View

2.
Daijo K, Kawaoka T, Nakahara T, Nagaoki Y, Tsuge M, Hiramatsu A . Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia. Clin J Gastroenterol. 2017; 10(4):383-387. DOI: 10.1007/s12328-017-0753-0. View

3.
Enns G, Berry S, Berry G, Rhead W, Brusilow S, Hamosh A . Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med. 2007; 356(22):2282-92. DOI: 10.1056/NEJMoa066596. View

4.
Haberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M . Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012; 7:32. PMC: 3488504. DOI: 10.1186/1750-1172-7-32. View

5.
Brassier A, Gobin S, Arnoux J, Valayannopoulos V, Habarou F, Kossorotoff M . Long-term outcomes in Ornithine Transcarbamylase deficiency: a series of 90 patients. Orphanet J Rare Dis. 2015; 10:58. PMC: 4443534. DOI: 10.1186/s13023-015-0266-1. View